A research report on attitudes regarding identifying and reporting harms associated with the use of DMHT and awareness of the MHRA Yellow Card Scheme.
Similar Posts
Side effects from drug interactions to be predicted by AI before reaching patients
The MHRA leads three new government-backed projects using AI-driven approaches to make medicines safer and bring treatments to patients more quickly.
Class 4 Medicines Defect Notification: Levetiracetam Accord 100mg/ml oral solution, Accord Healthcare Limited, UK, EL(25)A/40
Accord Healthcare Limited, UK has informed the MHRA that the Patient Information Leaflet (PIL) and Summary of Product Characteristics (SPC) do not contain all the required safety information.
Medical devices: get regulatory advice from the MHRA
How to apply for a regulatory advice meeting on medical devices and in vitro diagnostic devices.
Decision: Advertising Investigations: May 2025
Decisions made by the MHRA following investigations into complaints about advertising for licensed medicines.
Guidance: Operational Information Sharing
Guidance for Marketing Authorisation (MA) applicants on providing consent to share operational information during the MA application process.
Transparency data: Medicines and Healthcare products Regulatory Agency spending over £25,000: 2025 to 2026
Information on Medicines and Healthcare products Regulatory Agency spending over £25,000.